Answering Reviewer:

The notes from the reviewer bellow have all be edited and is in the new manuscript as bellow

1.Pediatricians or pediatricians; esophageal or oesophageal; They should be used with the same spelling throughout the article. DONE

2. Abstract: "We aim to describe the definition, presentation, diagnosis" pleased add "of eosinophilic esophagitis.". DONE

3. When the abbreviation is used for the first time, its full form should also be written; for example PPI Page 3; DONE

4. "Many patients have associated atopic disordered (change to disorders) including eczema, allergic rhinitis, respiratory symptoms related to asthma, and allergic reactions to food "Page 9, paragraph 3; DONE

5. costicosteroid – corticosteroid Page 9, paragraph 2; DONE

6. "A study by Rank et al. with 1051 patients proved PPI's therapeutic effectiveness and efficacy. [20]" Instead of this sentence, it would be more accurate to write it "in a systematic review by Rank et al. …." DONE

7. Page 13, last paragraph before Future Directions; abbreviation must be HRQoL. DONE

8. Page 14, last paragraph; "Cytosponge is a sponge-containing capsule after being swallowed it (delete will) collects esophageal tissue as it's pulled back, offering an easy method to assess EoE inflamatory activity [38]. DONE

9. Page 20, last paragraph; EoE inflammatory – EoE inflammatory DONE

10. The mechanisms by which the drugs used in treatment, especially biological agents, act should be written. For example, Dupilumab, a human monoclonal antibody that targets the interleukin-4 (IL-4) receptor alpha subunit of heterodimeric IL-4 and IL-13 receptors. DONE

11. Discussing the management under subgroups such as dietary elimination, pharmacological treatment, endoscopic interventions, and biological agents will make it easier for the reader to follow. DONE

12. It would be nice to provide brief information about the use/efficacy of other biological agents (e.g. mepolizumab, reslizumab, omalizumab, cendaakimab, dectrekumab, lirentelimab). DONE